Suggested remit: To appraise the clinical and cost effectiveness of ozanimod within its marketing authorisation for treating moderately to severely active ulcerative colitis.
Status In progress
Process STA 2018
ID number 3841

Provisional Schedule

Committee meeting: 1 12 July 2022
Expected publication 21 September 2022

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter


Companies sponsors Celgene (a Bristol-Myers Squibb company) (ozanimod)
Others Department of Health and Social Care
  NHS England
  NHS South Devon and Torbay CCG
  NHS Wiltshire CCG
  Welsh Government
Patient carer groups Bladder and Bowel Community
  Colostomy UK
  Crohn’s and Colitis UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Ulcerative Colitis UK
Professional groups Association of Coloproctology for Great Britain and Ireland
  British Geriatrics Society
  British Society of Gastroenterology
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association


Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AbbVie (adalimumab)
  Amgen Europe (adalimumab)
  Biogen Idec (adalimumab, infliximab)
  Boehringer Ingelheim International (adalimumab)
  Celltrion Healthcare (infliximab)
  Fresenius Kabi (adalimumab)
  Janssen-Cilag (ustekinumab)
  Merck Sharp & Dohme (infliximab, golimumab)
  Mylan (adalimumab)
  Napp Pharmaceuticals (infliximab)
  Pfizer (infliximab, tofacitinib)
  Samsung Bioepis UK (adalimumab, infliximab)
  Sandoz (adalimumab, infliximab)
  Takeda UK (vedolizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  Genomics England
  Cochrane UK
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
29 October 2021 Invitation to participate
29 October 2021 In progress. Invitation to Participate issued.
23 July 2021 We recently contacted all stakeholders for the appraisal of Ozanimod for treating moderate to severe ulcerative colitis [ID3841] regarding a delay to this topic for operational reasons. Ozanimod for treating moderate to severe ulcerative colitis has now been rescheduled into the work programme and the appraisal is due to start late October 2021 and will be discussed at committee in mid July 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
27 January 2021 - 24 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance